Cabaletta Bio Q4/FY2024 results: cash $164M, R&D spend up, protocol deviation in SSc trial

Cabaletta Bio, Inc.

2025-Q1 EPS reported -$0.71

Cash and equivalents $164M as of Dec 31, 2024, providing runway into first half of 2026.
R&D expenses for FY2024 were $97.2M, up from $55.4M in FY2023.
Enrolled 33 patients across RESET program as of Mar 14, 2025; FDA meeting on myositis trial designs on track for 1H25.
Protocol deviation in RESET-SSc: patient infused with fever developed grade 3 ICANS; IDMC recommended trial continue.
Expanded CDMO agreement with Lonza for rese-cel clinical product supply starting 2H25.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.